Compare LOW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOW | SNY |
|---|---|---|
| Founded | 1946 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.5B | 119.4B |
| IPO Year | N/A | N/A |
| Metric | LOW | SNY |
|---|---|---|
| Price | $244.41 | $48.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $277.40 | $61.50 |
| AVG Volume (30 Days) | ★ 2.8M | 2.5M |
| Earning Date | 11-19-2025 | 01-29-2026 |
| Dividend Yield | 1.96% | ★ 3.30% |
| EPS Growth | 0.73 | ★ 105.93 |
| EPS | ★ 12.06 | 8.67 |
| Revenue | ★ $84,255,000,000.00 | $53,890,648,839.00 |
| Revenue This Year | $3.89 | $1.73 |
| Revenue Next Year | $8.27 | $6.49 |
| P/E Ratio | $20.27 | ★ $10.94 |
| Revenue Growth | ★ 0.64 | N/A |
| 52 Week Low | $206.39 | $44.62 |
| 52 Week High | $274.98 | $60.12 |
| Indicator | LOW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 46.32 |
| Support Level | $239.54 | $48.16 |
| Resistance Level | $254.04 | $48.74 |
| Average True Range (ATR) | 4.42 | 0.64 |
| MACD | -0.59 | 0.05 |
| Stochastic Oscillator | 34.28 | 65.42 |
Lowe's is the second-largest home improvement retailer globally, with around 1,750 stores in the US, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its professional business clients to 30% from less than 20% in the past six years (set ot expand further with the acquisition of FBM). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.